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Triggering receptor expressed on myeloid cells 2 (TREM2) homozygous mutations cause Nasu-Hakola
disease, an early-onset recessive form of dementia preceded by bone cysts and fractures. The same
type of mutations has recently been shown to cause frontotemporal dementia (FTD) without the pres-
ence of any bone phenotype. Here, we further conﬁrm the association of TREM2 mutations with FTD-like
phenotypes by reporting the ﬁrst compound heterozygous mutation in a Turkish family.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
Nasu-Hakola disease (NHD, OMIM 221770), also known as
polycystic lipomembranous osteodysplasia with sclerosing leu-
koencephalopathy, is a rare autosomal recessive disease charac-
terized by a combination of progressive young-onset dementia
and multifocal bone cysts (Paloneva et al., 2001). In most Nasu-
Hakola patients, the clinical course of the disease can be divided
into 4 stages: (1) the latent stage with normal early development;
(2) the osseous stage beginning at the third decade of life, char-
acterized by pain and swelling in ankles and feet followed by
frequent bone fractures; (3) the early neuropsychiatric stage
occurring at the fourth decade of life, presenting with a frontal
lobe syndrome including euphoria and social disinhibition; and
(4) the late neuropsychiatric stage, characterized by profound
dementia, loss of mobility, and death usually by age of 50 yearsar Neuroscience, Institute of
ueen Square, London WC1N
833 1017.
).
r Inc. Open access under CC BY licens(Klunemann et al., 2005). NHD is caused by mutations in 1 of 2
genes: TYRO protein tyrosine kinaseebinding protein (TYROBP)
on chromosome 19q13.1 and triggering receptor expressed on
myeloid cells 2 (TREM2) on chromosome 6p21.1.
Recently, cases with homozygous mutations in TREM2 have been
described to present atypical phenotypes resembling behavioral
variant frontotemporal dementia (bvFTD) and lacking stage (2) of
the clinical picture described previously (Chouery et al., 2008;
Giraldo et al., 2013; Guerreiro et al., 2013b).
At present, 14 different mutations have been identiﬁed in TREM2
including nonsense, missense, small deletions, and splice site
homozygous mutations (Giraldo et al., 2013). Here, we report the
ﬁrst TREM2 compound heterozygous mutation identiﬁed in a
Turkish family presenting with an FTD-like phenotype.
2. Methods
2.1. Patients
The proband is currently being followed in the outpatient
clinic of the Behavioral Neurology and Movement Disorders Unit,
Istanbul Faculty of Medicine, Istanbul University. She was hospi-
talized in 2012 for a detailed neurologic workup. Written
informed consent was obtained from all family members, and thise.
Fig. 1. Pedigree of the family where the compound heterozygous mutation
p.[(Y38C)];[(D86V)] in TREM2 was found. The arrowhead indicates the proband. Black
ﬁlled symbols represent affected subjects with dementia. White symbols represent un-
affected family members. The TREM2 variants found are represented below each indi-
vidual showing segregation of the compound heterozygous mutation with the disease.
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University.
2.2. Genetic analysis
DNA was extracted from blood samples, according to standard
procedures. For the proband, all coding exons of TREM2 wereFig. 2. Magnetic resonance imaging of the proband. (A) Transverse T1-weighted image sh
recovery image demonstrates mild but diffuse hyperintense appearance of the white matter
image, there is marked thinning of the entire corpus callosum. (D) Coronal T2-weighted im
caudate nuclei.ampliﬁed by polymerase chain reaction (PCR) using Roche FastStart
PCR Master Mix (Roche Diagnostics Corp). The PCR products were
sequenced using the same forward and reverse primers (primers
available on request) with Applied Biosystems BigDye terminator
version 3.1 sequencing chemistry and run on an ABI3730XL genetic
analyzer as per the manufacturer’s instructions (Applied Bio-
systems). The sequences were analyzed using Sequencher software,
version 4.2 (Gene Codes). For family members, only exon 2 of
TREM2 was tested.3. Results
3.1. Case report
The proband is a 41-year-old female who presented with a 1-
year history of a change in personality. She had become increasingly
apathetic, and her husband reported that she had become less
empathic toward close family and friends, unexpectedly leaving her
husband and their child in the United States to move back to her
parents’ house in Turkey. At this time, her mother noticed that she
had started to become more perseverative in her behavior and
developing a change in food preference, eating more junk food. She
also started to have mild word-ﬁnding difﬁculties. She had been
previously ﬁt and well apart from having had 2 previous general-
ized tonic-clonic seizures (one 4 years earlier and one 2 years
earlier).
Her parents were originally from the same city (Erzincan)
with a population of about 225,000 inhabitants, located in the
eastern part of Turkey and were both clinically healthy. She had
2 siblings, a brother who was well and a sister who had also
developed progressive cognitive impairment and behavioral
problems with generalized tonic-clonic seizures starting in her
30s (Fig. 1).
She scored 44 on the Addenbrooke’s cognitive examination
(range 0e100, higher scores indicating better performance) and 28
on the frontal behavioral inventory (range 0e72, higher scores
indicating worse behavioral symptoms; disinhibition subscore 11,
negative behavior subscale score 17). Formal neuropsychometry
testing revealed deﬁcits in executive function, particularly abstract
thinking, planning, and inhibition. There was also evidence of lan-
guage dysfunction with nonﬂuent speech, anomia, and phonemic
paraphasias although comprehension and repetition were normal.
Other cognitive domains were relatively intact, and both neurologic
and general systemic examinations were normal.ows atrophy of the frontoparietal cortices. (B) Transverse ﬂuid-attenuated inversion
, mainly located in the neighborhood of the ventricle horns. (C) In sagittal T2-weighted
age reveals enlargement of the lateral and third ventricles with atrophy of the bilateral
Fig. 4. Computed tomography of the proband reveals symmetrical hyperdense lesions
resembling calciﬁcations in the globus pallidus.
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and parathyroid hormone. Cerebrospinal ﬂuid analysis revealed a
mild pleocytosis (10 lymphocytes per cubic millimeter) and
mildly increased protein (54 mg/dL) with positive unmatched
oligoclonal bands. Electroencephalography was normal. Magnetic
resonance imaging of the brain showed atrophy mainly located in
the frontal, lateral temporal, and parietal cortices and also the
caudate nuclei with marked thinning of the corpus callosum and
enlargement of the ventricular system. On T2 and ﬂuid-
attenuated inversion recovery imaging, there was evidence of
diffuse hyperintensities in the periventricular, frontal, and occi-
pitoparietal white matter (Fig. 2). There were also symmetrical
hypointense lesions bilaterally in the globus pallidus on T1, T2,
and ﬂuid-attenuated inversion recovery imaging (Fig. 3). These
were considered to be calciﬁcation because computed tomogra-
phy of the brain revealed marked hyperdense lesions (Fig. 4) in
the same areas. Further tests included a skeletal X-ray survey,
which showed no bone cysts.
3.2. Genetic analysis
In the proband, PCR and direct sequencing analysis of the 5
exons and exon-intron boundaries of TREM2 identiﬁed 2 different
missense heterozygous mutations: c.113A>G, p.Y38C and c.257A>T,
p.D86V in exon 2 (NM_018965.3).
To determine if the patient was a compound heterozygote, we
sequenced exon 2 in the parents. The father carried the p.Y38C
heterozygous variant and the mother carried the p.D86V also
heterozygous; thus, the proband carries a compound heterozygous
mutation: c.[113A>G];[257A>T]; p.[(Y38C)];[(D86V)].
To assess segregation of the mutation with the disease, we
sequenced 2 siblings, 1 affected and 1 unaffected. The compound
heterozygous mutation segregated with the disease, being present
in the affected siblings and absent in the unaffected, who carried
only one of the variants (p.Y38C) (Fig. 1).
None of these variants are reported on large genetic databases
(dbSNP version 137, 1000Genomes Project or Exome Variant Server,
NHLBI GO Exome Sequencing Project, Seattle, WA, http://evs.gs.
washington.edu/EVS/, accessed on May, 2013), but we have previ-
ously reported both changes in the Turkish population. Homozy-
gosity for the p.Y38C mutation was found in the only affected
subject from family 2, and p.D86V was found in heterozygosity in aFig. 3. Both T1 and ﬂuid-attenuated inversion recovery images dehealthy control individual from 76 Turkish controls screened for
TREM2 exon 2 mutations in our previous study (Guerreiro et al.,
2013b).
4. Discussion
Both homozygous and compound heterozygous mutations in
TYROBP are known to cause NHD (Kuroda et al., 2007). Homozygous
mutations in TREM2 also cause NHD. More recently, we and others
have found homozygous mutations in this gene to be associated
with bvFTD-like phenotype without any associated bone involve-
ment (Chouery et al., 2008; Giraldo et al., 2013; Guerreiro et al.,
2013b). Here, we report the ﬁrst compound heterozygous muta-
tion in TREM2, which was found to be associated with FTD pheno-
type in a Turkish family.monstrate symmetrical hypointense lesions in basal ganglia.
Table 1
Main features of all the patients described in the literature with TREM2 mutations presenting without an osseous phenotype
Chouery et al. (2008) Guerreiro et al. (2013b) Giraldo et al. (2013) Present study
Number of families 1 3 1 1
Geographic origin Lebanon Turkey Colombia Turkey
Sibling 1 Sibling 2 Sibling 3 Patient 1 Patient 2 Patient 3 Sibling 1 Sibling 2 Sibling 3 (index) Sibling 1 Sibling 2 (index)
Gender F F M M M M M F F F F
Diagnosis Early-onset dementia bvFTD like bvFTD bvFTD like
Age at onset (y) 30e35 20 Late 30s 33 50 45 47 32 36
Age at death (y) 50 Alive (50) 46 33 Alive (50) 45 Alive (55) NA Alive (48) Alive (40) Alive (41)
Initial symptoms Forgetfulness and fatigue Personality changes
with aggressive
behavior
Personality changes
with aggressive and
perseverative
behavior
Generalized T-C
seizure
Altered social behavior and oropharyngeal tic
in 1 sibling
Behavioral changes
with nonﬂuent
aphasia
Generalized T-C
seizures
Other symptoms Neuropsychiatric signs
UI and impotence
Generalized T-C
seizures
Cognitive
impairment
Ophthalmoplegia
with bradykinesia
and brisk deep
tendon reﬂexes
Cognitive
impairment
Bradykinesia,
apraxia þ postural
instability
Personality changes
with progressive
behavioral
problems
Bradykinesia þ
mild postural
instability
Visual
hallucinations
UI
New onset of substance use
Complex partial seizures
Severe pan-frontal syndrome and cognitive
decline
Generalized T-C
seizures
Bradykinesia þ
postural instability
UI
Cognitive
deterioration þ
behavioral changes
Brain imaging Diffuse brain and cortical atrophy
in the polar region of the tempo-
ral lobes
CC thinning
Stenosis of the aqueduct of
sylvius þ arachnoid cyst in the
posterior cranial fossa
Periventricular leucoaraiosis
Relative enlargement of peri-
vascular Virchow-Robin spaces
No lenticulopallidal calciﬁcations
Frontal and tempo-
ral cortical atrophy
CC thinning
Diffuse conﬂuent
WM abnormalities
No calciﬁcation of
the basal ganglia
Frontal cortical at-
rophy with marked
ventricular
enlargement
CC thinning
Conﬂuent periven-
tricular WM
abnormalities
Cortical atrophy
predominantly
affecting the frontal
loes
Diffuse conﬂuent
WM lesions
No calciﬁcation of
the basal ganglia
Asymmetric bifrontal atrophy Frontoparietal and
temporal cortical
atrophy
Marked CC thinning
Diffuse periven-
tricular and frontal
WM lesions
No calciﬁcation of
the basal ganglia
Global cortical at-
rophy mainly in
frontal, lateral tem-
poral and parietal
cortices and
caudate nuclei
CC thinning
Enlargement of
ventricular system
Hyperintensity in
periventricular,
frontal and occipi-
toparietal WM
Bilateral calciﬁca-
tion in globus
pallidus
Family history No history of dementia in the
parents
History of
dementia,
psychotic disorders,
and epilepsy in the
family
One brother,
paternal uncle, and
maternal
grandfather
presented late-
onset memory
impairment
No family history of
cognitive or
behavioral
impairment
One paternal uncle and brother had similar
symptoms
No family history of cognitive or behavioral
impairment
TREM2 mutation c.40þ3delAGG c.97C>T; p.Q33X c.197C>T; p.T66M c.113A>G; p.Y38C c.594G>A; p.W198X c.[113A>G];[257A>T]; p.[(Y38C)];[(D86V)]
Key: bvFTD, behavioral variant frontotemporal dementia; CC, corpus callosum; F, female; M, male; NA, not applicable; T-C, tonic-clonic; UI, urinary incontinence; WM, white matter.
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R. Guerreiro et al. / Neurobiology of Aging 34 (2013) 2890.e1e2890.e5 2890.e5The proband in the family here described was identiﬁed
because she presented a clinical picture similar to the 3 previous
bvFTD-like cases with homozygous TREM2 mutations we reported
before (Guerreiro et al., 2013b). In addition to these 3 Turkish
cases, 2 other families were also reported to carry homozygous
mutations in TREM2, presenting with a bvFTD-like phenotype
without bone cysts. Chouery et al. (2008) described a Lebanese
family presenting with a young-onset dementia without bone
cysts where 3 affected subjects carried a deletion (c.40þ3delAGG)
in the 50 consensus donor splice site in intron 1 of TREM2. These
affected individuals developed personality and behavioral
changes at the age of 30e35 years, culminating in severe de-
mentia. Brain magnetic resonance imaging showed cortical atro-
phy with periventricular white matter disease (Chouery et al.,
2008). More recently, Giraldo et al. (2013) reported a novel ho-
mozygous nonsense mutation (p.W198X) in a Colombian family
with an autosomal recessive pattern of inheritance of FTD, also
without bone cysts. These patients started to develop behavioral
and personality changes around the age of 45e50 years. Similar
to this case and the previously described Turkish cases, the
affected siblings in the Colombian family also developed seizures
(Table 1).
Dementia in the form of an early-onset personality change,
resembling bvFTD, seems to be the most common feature of all
these reported cases, most often associated with seizures and
characteristic imaging ﬁndings, such as callosal atrophy and diffuse
white matter lucency. Familial FTD accounts for >40% of all cases,
and to date, several genetic causes of the phenotype have been
described. However, all the 7 genes with mutations causing familial
FTD (i.e., MAPT, GRN, C9ORF72, VCP, CHMP2B, TARDBP, and FUS) are
dominantly inherited. TREM2 mutations appear to be the ﬁrst
addition to this list as a recessively inherited genetic cause. We
suggest that a family history of consanguinity along with somewhat
atypical features, such as seizures and callosal atrophy, in a patient
presenting with a bvFTD phenotype should prompt the diagnosti-
cian to look for a likely TREM2 homozygous or compound hetero-
zygous mutation. In the same line of reasoning, this genetic cause
should be included in the differential diagnosis of young-onset
dementia with seizures. Hitherto, adult neuronal ceroid lip-
ofuscinosis (also known as Kufs disease) remains the prototype of
this presentation.
The precise molecular and cellular mechanisms underlying the
pathogenesis of these diseases are not yet known. There seems to
be no correlation between the type of mutation and the associated
phenotype because nonsense, splice site, and missense mutations
have now been associated with FTD cases. TREM2 is a membrane
protein that forms a receptor-signaling complex with TYROBP,
triggering the activation of the immune response, differentiation of
dendritic cells and osteoclasts, and phagocytosis in microglia. It is
interesting to note that a heterozygous variant (p.R47H) in TREM2
has recently been shown to increase the risk for Alzheimer’s disease
(Guerreiro et al., 2013a; Jonsson et al., 2013). This suggests that
TREM2 is part of a functional network involved in different
neurodegenerative dementias (FTD, Alzheimer’s disease, and Nasu-
Hakola), but besides the fact that homozygous mutations cause an
early-onset and more severe disease, whereas heterozygousvariants increase the risk for a late-onset disorder, it is not possible
to establish a speciﬁc correlation between genotype and
phenotype.
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